CR8331A - Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente - Google Patents

Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente

Info

Publication number
CR8331A
CR8331A CR8331A CR8331A CR8331A CR 8331 A CR8331 A CR 8331A CR 8331 A CR8331 A CR 8331A CR 8331 A CR8331 A CR 8331A CR 8331 A CR8331 A CR 8331A
Authority
CR
Costa Rica
Prior art keywords
domain
antibody
cdr1
cdr2
seq
Prior art date
Application number
CR8331A
Other languages
English (en)
Inventor
Borsi Laura
Carnemolla Barbara
Balza Enrica
Castellani Patrizia
Zardi Luciano
Friebe Matthias
Hilger Christoph-Stephan
Original Assignee
Bayer Schering Pharma Ag
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Philogen Spa filed Critical Bayer Schering Pharma Ag
Publication of CR8331A publication Critical patent/CR8331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se relaciona con el reconocimiento dirigido [targeting] de la vasculatura tumoral usando moleculas de anticuerpo marcadas radioactivamente.
CR8331A 2003-09-10 2006-04-06 Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente CR8331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50188103P 2003-09-10 2003-09-10
EP03255633A EP1514561A1 (en) 2003-09-10 2003-09-10 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Publications (1)

Publication Number Publication Date
CR8331A true CR8331A (es) 2006-10-04

Family

ID=34130349

Family Applications (2)

Application Number Title Priority Date Filing Date
CR8331A CR8331A (es) 2003-09-10 2006-04-06 Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente
CR20110168A CR20110168A (es) 2003-09-10 2011-03-24 Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-b de fibronectina marcado radioactivamente (divisional solicitud 8331)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20110168A CR20110168A (es) 2003-09-10 2011-03-24 Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-b de fibronectina marcado radioactivamente (divisional solicitud 8331)

Country Status (28)

Country Link
US (2) US20050074401A1 (es)
EP (3) EP1514561A1 (es)
JP (1) JP2007505065A (es)
KR (1) KR101129161B1 (es)
CN (1) CN100482285C (es)
AT (1) ATE499949T1 (es)
AU (2) AU2004269897B2 (es)
BR (1) BRPI0414272A (es)
CA (1) CA2536256C (es)
CR (2) CR8331A (es)
DE (1) DE602004031635D1 (es)
DK (1) DK1663320T3 (es)
EA (1) EA010653B1 (es)
EC (1) ECSP066499A (es)
ES (1) ES2361743T3 (es)
HK (1) HK1092375A1 (es)
IL (1) IL173560A0 (es)
ME (1) MEP13108A (es)
NO (1) NO20061619L (es)
NZ (1) NZ545640A (es)
PL (1) PL1663320T3 (es)
PT (1) PT1663320E (es)
RS (1) RS20060176A (es)
SG (1) SG162760A1 (es)
SI (1) SI1663320T1 (es)
UA (1) UA89759C2 (es)
WO (1) WO2005023318A1 (es)
ZA (1) ZA200602014B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
JP2005534283A (ja) * 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2085095B1 (en) * 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
PL2281006T3 (pl) 2008-04-30 2018-01-31 Immunogen Inc Środki łączące i ich zastosowania
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
CN104395342B (zh) * 2013-06-06 2017-07-04 合肥立方制药股份有限公司 人源抗纤连蛋白ed‑b结构域的抗体及其用途
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP7352040B2 (ja) * 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
WO2023131611A1 (en) 2022-01-04 2023-07-13 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
PT1257297E (pt) 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
RU2352582C2 (ru) * 2002-01-03 2009-04-20 Шеринг Акциенгезельшафт Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей
JP2005534283A (ja) * 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化

Also Published As

Publication number Publication date
BRPI0414272A (pt) 2006-11-07
SI1663320T1 (sl) 2011-06-30
EP1514561A1 (en) 2005-03-16
ATE499949T1 (de) 2011-03-15
ECSP066499A (es) 2006-10-10
EA200600494A1 (ru) 2006-08-25
DE602004031635D1 (de) 2011-04-14
AU2010200271A1 (en) 2010-02-18
CN100482285C (zh) 2009-04-29
KR20060118430A (ko) 2006-11-23
ES2361743T3 (es) 2011-06-21
EP1663320B1 (en) 2011-03-02
SG162760A1 (en) 2010-07-29
EA010653B1 (ru) 2008-10-30
KR101129161B1 (ko) 2012-03-28
PL1663320T3 (pl) 2011-07-29
UA89759C2 (ru) 2010-03-10
CR20110168A (es) 2011-06-03
AU2004269897A1 (en) 2005-03-17
HK1092375A1 (en) 2007-02-09
CA2536256A1 (en) 2005-03-17
MEP13108A (en) 2011-05-10
US20050074401A1 (en) 2005-04-07
CN1849144A (zh) 2006-10-18
PT1663320E (pt) 2011-06-07
ZA200602014B (en) 2007-05-30
NZ545640A (en) 2009-05-31
RS20060176A (en) 2008-08-07
EP1663320A1 (en) 2006-06-07
NO20061619L (no) 2006-04-10
DK1663320T3 (da) 2011-06-06
CA2536256C (en) 2013-02-26
AU2004269897B2 (en) 2009-11-05
US20090214423A1 (en) 2009-08-27
EP2246070A2 (en) 2010-11-03
IL173560A0 (en) 2006-07-05
JP2007505065A (ja) 2007-03-08
WO2005023318A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
CR8331A (es) Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-8 de fibronectina marcado radioactivamente
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
Tang et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
PE20020871A1 (es) Moleculas de enlace terapeuticas
HRP20160270T1 (hr) Monoklonska antitijela protiv glipikana-3
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
CN109963591A (zh) B7h3抗体-药物偶联物及其医药用途
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BR0306808A (pt) Anticorpos monoclonais humanos contra cd30
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CR6425A (es) Anticuerpos monoclonales humanos de ctla-4
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
BR0112086A (pt) Anticorpos para mcp-1 humano
ATE414151T1 (de) Antikörper gegen eotaxin und deren verwendung
CA2478414A1 (en) Selective targeting of tumor vasculature using antibody molecules
PE20060019A1 (es) Anticuerpo monoclonal humanizado contra isoforma cd45rb
BR0210648A (pt) Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
RU2019113758A (ru) Конъюгат "цистеин-модифицированное антитело-лекарственное средство" и способ его получения
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека